{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:27:49Z","timestamp":1770139669666,"version":"3.49.0"},"reference-count":79,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cutaneous basal cell carcinoma (BCC) is the most common type of human tumor, and its incidence rate is increasing worldwide. Up until a few years ago, therapeutic options have been limited for patients with advanced BCC (including metastatic and locally-advanced BCC). Over the last few years, promising systemic therapies have been investigated for the treatment of advanced BCC. In particular, the Hedgehog signaling inhibition has shown remarkable results for this population. Hedgehog inhibitors, represented by vismodegib and sonidegib, have been approved by the Food and Drug Administration and the European Medicines Agency for the treatment of both locally advanced and metastatic BCC, with, generally, a good safety profile. Notwithstanding the late onset of BCC in the global population, associated with life expectancy increase, only a few clinical trials have evaluated the efficacy and safety profile of Hedgehog inhibitors in this complex and neglected population. Herein, we review the major mechanisms implicated in the pathogenesis of BCC focusing on the Hedgehog signaling pathway and its therapeutic role in the elderly population. Finally, we report two case reports of BCC elderly patients in order to demonstrate both efficacy and safety of the Hedgehog inhibitors.<\/jats:p>","DOI":"10.3390\/ijms21228596","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T21:48:52Z","timestamp":1605563332000},"page":"8596","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature"],"prefix":"10.3390","volume":"21","author":[{"given":"Anna","family":"Passarelli","sequence":"first","affiliation":[{"name":"Department of Onco-Hematology, Unit of Medical Oncology, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), 85028 Rionero in Vulture, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Galdo","sequence":"additional","affiliation":[{"name":"Department of Onco-Hematology, Oncologic Dermatology Unit, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), IRCCS-CROB, 85028 Rionero in Vulture, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8196-704X","authenticated-orcid":false,"given":"Michele","family":"Aieta","sequence":"additional","affiliation":[{"name":"Department of Onco-Hematology, Unit of Medical Oncology, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), 85028 Rionero in Vulture, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Fabrizio","sequence":"additional","affiliation":[{"name":"Division of Plastic Surgery, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), IRCCS-CROB, 85028 Rionero in Vulture, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Villonio","sequence":"additional","affiliation":[{"name":"Radiology Department, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), IRCCS-CROB, 85028 Rionero in Vulture, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Conca","sequence":"additional","affiliation":[{"name":"Department of Onco-Hematology, Unit of Medical Oncology, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), 85028 Rionero in Vulture, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_2","first-page":"232","article-title":"Observations respecting an ulcer of peculiar character, which attacks the eyelids and other parts of the face","volume":"4","author":"Jacob","year":"1827","journal-title":"Dublin Hosp. Rep. Commun. Med. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1001\/jamadermatol.2015.1188","article-title":"Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998\u20132012","volume":"151","author":"Asgari","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clindermatol.2019.06.004","article-title":"Aging and the treatment of basal cell carcinoma","volume":"37","author":"Sreekantaswamy","year":"2019","journal-title":"Clin. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1155\/2011\/392151","article-title":"Neglected basal cell carcinomas in the 21st century","volume":"2011","author":"Varga","year":"2011","journal-title":"J. Skin Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.amjmed.2016.03.003","article-title":"Treatment of Basal Cell Carcinoma in the Elderly: What non-dermatologists need to know","volume":"129","author":"Wiznia","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/jco.2014.32.15_suppl.9013","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study [abstract]","volume":"32","author":"Sekulic","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/archderm.1987.01660270078019","article-title":"Surgical margins for basal cell carcinoma","volume":"123","author":"Wolf","year":"1987","journal-title":"Arch. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/PRS.0b013e3181ea450d","article-title":"What is the best surgical margin for a Basal cell carcinoma: A meta-analysis of the literature","volume":"126","author":"Gulleth","year":"2010","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1524-4725.1992.tb03307.x","article-title":"Recurrence rated of treated basal cell carcinoma. Part 3: Surgical excision","volume":"18","author":"Silverman","year":"1992","journal-title":"J. Dermatol. Surg. Oncol."},{"key":"ref_12","unstructured":"National Comprehensive Cancer Network (2019). NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer, National Comprehensive Cancer Network. Version, I."},{"key":"ref_13","first-page":"293","article-title":"Effect of age on wound healing in healthy human beings","volume":"112","author":"Holt","year":"1992","journal-title":"Surgery"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000342344","article-title":"Age-related aspects of cutaneous wound healing: A mini-review","volume":"59","author":"Sgonc","year":"2013","journal-title":"Gerontology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jgs.13332","article-title":"Chronic wound repair and healing in older adults: Current status and future research","volume":"63","author":"Gould","year":"2015","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1524-4725.1989.tb03166.x","article-title":"Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: Implications for patient follow-up","volume":"5","author":"Rowe","year":"1989","journal-title":"J. Dermatol. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1524-4725.1989.tb03249.x","article-title":"Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma","volume":"15","author":"Rowe","year":"1989","journal-title":"J. Dermatol. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/hed.20605","article-title":"Surgery for head and neck skin tumors in the elderly","volume":"29","author":"Dhiwakar","year":"2007","journal-title":"Head Neck"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.0022-202X.2004.23546.x","article-title":"Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin)","volume":"124","author":"Eide","year":"2005","journal-title":"J. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/bjd.14308","article-title":"Mohs micrographic surgery for basal cell carcinoma: Evaluation of the indication criteria and predictive factors for extensive subclinical spread","volume":"174","author":"Hoorens","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1524-4725.1992.tb03509.x","article-title":"Basal cell carcinoma treated with Mohs surgery. A comparison of 54 younger patients with 1050 older patients","volume":"18","author":"Dinehart","year":"1992","journal-title":"J. Dermatol. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jdv.14586","article-title":"Mohs micrographic surgery in the elderly: Comparison of tumours, surgery and first-year follow-up in patients younger and older than 80 years old in REGESMOHS","volume":"32","author":"Redondo","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10006-010-0215-z","article-title":"Multivariate analysis of the influence of patient-, tumor-, and management-related factors on the outcome of surgical therapy for facial basal-cell carcinoma","volume":"14","author":"Mueller","year":"2010","journal-title":"Oral. Maxillofac. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/jgs.14202","article-title":"Skin Cancer in U.S. Elderly Adults: Does Life Expectancy Play a Role in Treatment Decisions?","volume":"64","author":"Linos","year":"2016","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2010.03.027","article-title":"The use of brachytherapy in the treatment of nonmelanoma skin cancer: A review","volume":"65","author":"Alam","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archderm.1960.01580020039006","article-title":"Curettage and electrodesiccation in the treatment of skin cancer","volume":"82","author":"Knox","year":"1960","journal-title":"Arch. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1524-4725.1991.tb03425.x","article-title":"Recurrence rates of treated basal cell carcinomas: Part 2: Curettage-electrodessication","volume":"17","author":"Silverman","year":"1991","journal-title":"J. Dermatol. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2006.07.007","article-title":"Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation","volume":"56","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","first-page":"9","article-title":"History of cryotherapy","volume":"11","author":"Freiman","year":"2005","journal-title":"Dermatol. Online J."},{"key":"ref_30","first-page":"566","article-title":"Evidence-based review of use of cryosurgery in treatment of BCC","volume":"29","author":"Kokoszka","year":"2003","journal-title":"Dermatol. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/ijd.13168","article-title":"Intralesional cryosurgery for the treatment of basal cell carcinoma of the lower extremities in elderly subjects: A feasibility study","volume":"55","author":"Sommer","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"571734","DOI":"10.1155\/2011\/571734","article-title":"Nonsurgical treatment options for basal cell carcinoma","volume":"2011","author":"Lien","year":"2011","journal-title":"J. Skin Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/14764172.2017.1349321","article-title":"The use of lasers in the treatment of skin cancer: A review","volume":"19","author":"Mirza","year":"2017","journal-title":"J. Cosmet. Laser Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/lsm.21035","article-title":"Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: Response and follow up 12\u201321 months after treatment","volume":"43","author":"Konnikov","year":"2011","journal-title":"Lasers Surg. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/DSS.0000000000001106","article-title":"Pulsed CO2 laser ablation of superficial basal cell of limbs and trunk: A comparative randomized clinical trial with cryotherapy and surgical ablation","volume":"43","author":"Zane","year":"2017","journal-title":"Dermatol. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/bjd.14414","article-title":"Carbon dioxide laser ablation of basal cell carcinoma with visual guidance by reflectance confocal microscopy: A proof-of-principle pilot study","volume":"174","author":"Hibler","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_37","first-page":"1101","article-title":"Topical immunomodulation in dermatology: Potential of toll-like receptor agonists","volume":"30","author":"Hengge","year":"2004","journal-title":"Dermatol. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3389\/fonc.2019.01148","article-title":"Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells","volume":"9","author":"Tucci","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/bjd.16838","article-title":"Conventional and combination topical photodynamic therapy for basal cell carcinoma: Systematic re-view and meta-analysis","volume":"179","author":"Collier","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jid.2016.03.043","article-title":"Three-year follow-up results of photodynamic therapy vs. Imiquimod vs. Fluorouracil for treatment ofsuperficial basal cell carcinoma: A single-blind, noninferiority, randomized controlled trial","volume":"136","author":"Roozeboom","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1101\/gad.1693608","article-title":"Hedgehog: Functions and mechanisms","volume":"22","author":"Varjosalo","year":"2008","journal-title":"Genes Dev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1524-475X.2008.00430.x","article-title":"Hedgehog signalling is essential for normal wound healing","volume":"16","author":"Le","year":"2008","journal-title":"Wound Repair Regen."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ncb2031","article-title":"Identification of the cell lineage at the origin of basal cell carcinoma","volume":"12","author":"Youssef","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ccr.2010.11.007","article-title":"Basal cell carcinomas arise from hair follicle stem cells in Ptch1(\u00b1) mice","volume":"19","author":"Wang","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrc2503","article-title":"Basal cell carcinomas: Attack of the hedgehog","volume":"8","author":"Epstein","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1038\/s41467-018-05220-6","article-title":"Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer","volume":"9","author":"Cazet","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_47","first-page":"634","article-title":"The GLI Gene Encodes a Nuclear Protein Which Binds Specific Sequences in the Human Genome","volume":"10","author":"Kinzler","year":"1990","journal-title":"Mol. Cell. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1242\/dev.124.7.1313","article-title":"A Binding Site for Gli Proteins Is Essential for HNF-3beta Floor Plate Enhancer Activity in Transgenics and Can Respond to Shh In Vitro","volume":"124","author":"Sasaki","year":"1997","journal-title":"Development"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41439-019-0041-2","article-title":"A healthy individual with a homozygous PTCH2 frameshift variant: Are variants of PTCH2 associated with nevoid basal cell carcinoma syndrome?","volume":"6","author":"Altaraihi","year":"2019","journal-title":"Hum. Genome Var."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.1038\/sj.onc.1204946","article-title":"PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer","volume":"20","author":"Ling","year":"2001","journal-title":"Oncogene"},{"key":"ref_51","first-page":"62","article-title":"Digging a hole under Hedgehog: Downstream inhibition as an emerging anticancer strategy","volume":"1856","author":"Coni","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Sekulic, A., Migden, M.R., Basset-Seguin, N., Garbe, C., Gesierich, A., Lao, C.D., Miller, C., Mortier, L., Murrell, D.F., and Hamid, O. (2017). Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3286-5"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"Hauschild","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","article-title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): A randomised, regimen-controlled, double-blind, phase 2 trial","volume":"18","author":"Dreno","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/bdrb.21093","article-title":"Embryofetal development study of vismodegib, a hedgehog pathway inhibitor, in rats","volume":"101","author":"Morinello","year":"2014","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11523-017-0545-y","article-title":"Retreatment with vismodegib after progression in advanced basal cell carcinoma: First-time report of a single-institution experience","volume":"13","author":"Alfieri","year":"2018","journal-title":"Target. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1021\/ml1000307","article-title":"Discovery of NVP- LDE225, a potent and selective smoothened antagonist","volume":"1","author":"Pan","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1158\/1078-0432.CCR-13-1710","article-title":"A phase I, multicenter, open-label, first-in-human, dose escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors","volume":"20","author":"Rodon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two dif- ferent doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial","volume":"16","author":"Migden","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/jdv.14542","article-title":"Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study","volume":"32","author":"Lear","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6121760","DOI":"10.1155\/2017\/6121760","article-title":"A matching- adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma","volume":"2017","author":"Odom","year":"2017","journal-title":"J. Skin Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study","volume":"182","author":"Dummer","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1078-0432.CCR-14-2110","article-title":"Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma","volume":"21","author":"Otsuka","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"76118","DOI":"10.18632\/oncotarget.12660","article-title":"Safety and efficacy of vismodegib in patients aged \u226565 years with advanced basal cell carcinoma","volume":"7","author":"Chang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1001\/jamadermatol.2015.4592","article-title":"Effective and tolerable treatment of advanced basal cell carcinoma with Vismodegib despite renal insufficiency","volume":"152","author":"Maul","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e13108","DOI":"10.1111\/dth.13108","article-title":"Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities","volume":"32","author":"Spallone","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1684\/ejd.2016.2826","article-title":"Immunohistochemical markers of advanced basal cell carcinoma: CD56 is associated with a lack of response to vismodegib","volume":"26","author":"Castillo","year":"2016","journal-title":"Eur. J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41598-020-58117-0","article-title":"Gene-Related Response of Basal Cell Carcinoma to Biologic Treatment with Vismodegib","volume":"10","author":"Sternfeld","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e1387706","DOI":"10.1080\/2162402X.2017.1387706","article-title":"Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma","volume":"7","author":"Tucci","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"106132","DOI":"10.18632\/oncotarget.22190","article-title":"Immune system and melanoma biology: A balance between immuno- surveillance and immune escape","volume":"8","author":"Passarelli","year":"2017","journal-title":"Oncotarget"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"16037","DOI":"10.1038\/npjgenmed.2016.37","article-title":"Metastatic basal cell carcinoma with amplification of PD-L1: Exceptional response to anti-PD1 therapy","volume":"1","author":"Ikeda","year":"2016","journal-title":"NPJ Genom. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e1404217","DOI":"10.1080\/2162402X.2017.1404217","article-title":"Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies","volume":"7","author":"Goodman","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11523-019-00648-2","article-title":"Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma","volume":"14","author":"Gutzmer","year":"2019","journal-title":"Target. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Passarelli, A., Tucci, M., Mannavola, F., Felici, C., and Silvestris, F. (2019). The metabolic milieu in melanoma: Role of immune suppression by CD73\/adenosine. Tumor Biol., 42.","DOI":"10.1177\/1010428319837138"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3389\/fimmu.2020.01479","article-title":"Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance","volume":"11","author":"Passarelli","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40425-018-0439-2","article-title":"Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: A case report and review of the literature","volume":"6","author":"Sabbatino","year":"2018","journal-title":"J. Immunother. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/22\/8596\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:33:31Z","timestamp":1760178811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/22\/8596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,14]]},"references-count":79,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["ijms21228596"],"URL":"https:\/\/doi.org\/10.3390\/ijms21228596","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,14]]}}}